These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20200357)

  • 21. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
    Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
    Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway.
    Endo A; Tomizawa D; Aoki Y; Morio T; Mizutani S; Takagi M
    Cancer Sci; 2016 Dec; 107(12):1745-1754. PubMed ID: 27627705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
    Melo-Cardenas J; Xu Y; Wei J; Tan C; Kong S; Gao B; Montauti E; Kirsammer G; Licht JD; Yu J; Ji P; Crispino JD; Fang D
    Blood; 2018 Jul; 132(4):423-434. PubMed ID: 29844011
    [No Abstract]   [Full Text] [Related]  

  • 25. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis.
    Zhao Z; Chen CC; Rillahan CD; Shen R; Kitzing T; McNerney ME; Diaz-Flores E; Zuber J; Shannon K; Le Beau MM; Spector MS; Kogan SC; Lowe SW
    Nat Genet; 2015 May; 47(5):539-43. PubMed ID: 25822087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
    Cox AD; Der CJ; Philips MR
    Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
    Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
    Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
    Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
    Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
    Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia.
    Gu C; Feng M; Yin Z; Luo X; Yang J; Li Y; Li T; Wang R; Fei J
    Oncotarget; 2016 Apr; 7(15):20561-73. PubMed ID: 26967392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GOLGA7 is essential for NRAS trafficking from the Golgi to the plasma membrane but not for its palmitoylation.
    Liu C; Jiao B; Wang P; Zhang B; Gao J; Li D; Xie X; Yao Y; Yan L; Qin Z; Liu P; Ren R
    Cell Commun Signal; 2024 Feb; 22(1):98. PubMed ID: 38317235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
    Nussinov R; Tsai CJ; Jang H
    Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
    Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
    Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular biology of chronic myeloid leukemia.
    Maru Y
    Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.
    Caraffini V; Geiger O; Rosenberger A; Hatzl S; Perfler B; Berg JL; Lim C; Strobl H; Kashofer K; Schauer S; Beham-Schmid C; Hoefler G; Geissler K; Quehenberger F; Kolch W; Athineos D; Blyth K; Wölfler A; Sill H; Zebisch A
    Haematologica; 2020; 105(2):375-386. PubMed ID: 31097632
    [No Abstract]   [Full Text] [Related]  

  • 37. Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice.
    Cutts BA; Sjogren AK; Andersson KM; Wahlstrom AM; Karlsson C; Swolin B; Bergo MO
    Blood; 2009 Oct; 114(17):3629-32. PubMed ID: 19710506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-translational processing of purified human K-ras in Xenopus oocytes.
    Kaplan JB; Sass PM
    Cancer Commun; 1991; 3(12):383-8. PubMed ID: 16296004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
    Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
    Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth.
    Remsberg JR; Suciu RM; Zambetti NA; Hanigan TW; Firestone AJ; Inguva A; Long A; Ngo N; Lum KM; Henry CL; Richardson SK; Predovic M; Huang B; Dix MM; Howell AR; Niphakis MJ; Shannon K; Cravatt BF
    Nat Chem Biol; 2021 Aug; 17(8):856-864. PubMed ID: 33927411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.